Silence Therapeutics (SLN): Invus and Avicenna entities report 7.0% stake via Debbane

Rhea-AI Filing Summary

Silence Therapeutics plc is the subject of an updated ownership report by several affiliated investment entities and Raymond Debbane. As of June 30, 2026, Invus Public Equities, L.P. beneficially held 8,707,287 ordinary shares, represented by 2,902,429 American Depositary Shares (ADSs). Avicenna Life Sci Master Fund LP held 1,227,027 shares, represented by 409,009 ADSs. Each ADS represents three ordinary shares. Based on 141,703,840 shares outstanding as of April 30, 2026, Invus-related entities report beneficial ownership of 6.1% of the class and Avicenna-related entities 0.9%, while Raymond Debbane may be deemed to beneficially own 9,934,314 shares (7.0%) through his control of the reporting entities. The reporting group certifies the holdings are not for the purpose of changing or influencing control of Silence Therapeutics.

Key Figures

Invus Public Equities shares: 8,707,287 shares Invus Public Equities ADSs: 2,902,429 ADSs Avicenna Fund shares: 1,227,027 shares +5 more

8 metrics

Invus Public Equities shares 8,707,287 shares Beneficially held ordinary shares as of June 30, 2026

Invus Public Equities ADSs 2,902,429 ADSs ADSs directly held, each representing three ordinary shares

Avicenna Fund shares 1,227,027 shares Ordinary shares beneficially held via 409,009 ADSs

Avicenna Fund ADSs 409,009 ADSs ADSs directly held, each representing three ordinary shares

Debbane total beneficial shares 9,934,314 shares Ordinary shares he may be deemed to beneficially own, 7.0% of class

Shares outstanding 141,703,840 shares Ordinary shares outstanding as of April 30, 2026

Invus ownership percentage 6.1 % Percentage of ordinary shares beneficially owned by Invus Public Equities

Avicenna ownership percentage 0.9 % Percentage of ordinary shares beneficially owned by Avicenna Fund

Key Terms

American Depositary Shares, beneficially own, sole dispositive power, percent of class, +1 more

5 terms

American Depositary Shares financial

"holds an aggregate of 2,902,429 American Depositary Shares ("ADSs"), each of which ADS represents"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

beneficially own financial

"may be deemed to beneficially own the Shares beneficially held by Invus Public Equities"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

sole dispositive power financial

"5 | Sole Voting Power 8,707,287.00 6 | Shared Voting Power 0.00 7 | Sole Dispositive Power 8,707,287.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

percent of class financial

"Percent of class: As of June 30, 2026, each of the Reporting Persons may be deemed"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

Reporting Persons financial

"The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons.""

FAQ

What percentage of Silence Therapeutics (SLN) does Invus Public Equities own?

Invus Public Equities, L.P. reports beneficial ownership of 6.1% of Silence Therapeutics’ ordinary shares, holding 8,707,287 shares represented by 2,902,429 ADSs, with each ADS corresponding to three ordinary shares.

How many Silence Therapeutics (SLN) shares does Raymond Debbane beneficially own?

Raymond Debbane may be deemed to beneficially own 9,934,314 ordinary shares of Silence Therapeutics, representing 7.0% of the class, through his control of the Invus and Avicenna-related reporting entities listed in the filing.

What is the ADS structure for Silence Therapeutics (SLN) in this ownership report?

The report states that each American Depositary Share (ADS) of Silence Therapeutics represents three ordinary shares with a nominal value of 0.05 GBP per share, and positions are described both in ADSs and underlying ordinary shares.

How many Silence Therapeutics (SLN) shares are outstanding in calculating ownership percentages?

Ownership percentages are calculated using 141,703,840 ordinary shares outstanding as of April 30, 2026, based on information from Silence Therapeutics’ Form 10-Q filed on May 7, 2026.

Are the Invus and Avicenna holdings in Silence Therapeutics (SLN) intended to influence control?

The reporting persons certify that the securities “were not acquired and are not held for the purpose of or with the effect of changing or influencing the control” of Silence Therapeutics, other than limited nomination-related activities.

What is Avicenna Life Sci Master Fund’s position in Silence Therapeutics (SLN)?

Avicenna Life Sci Master Fund LP beneficially holds 1,227,027 ordinary shares of Silence Therapeutics, represented by 409,009 ADSs, corresponding to 0.9% of the outstanding ordinary shares as of the referenced dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 11:13 AM Accepted by SEC EDGAR 08/13/2026 - 11:13 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

Silence Therapeutics plc

(Name of Issuer)

Ordinary share, nominal value 0.05 GBP per share

(Title of Class of Securities)

82686Q101

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 82686Q101

1

Names of Reporting Persons

Invus Public Equities, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

BERMUDA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,707,287.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,707,287.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,707,287.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Invus Public Equities, L.P. holds an aggregate of 2,902,429 American Depositary Shares ("ADSs"), each of which ADS represents three ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer").

SCHEDULE 13G

CUSIP Number(s): 82686Q101

1

Names of Reporting Persons

Invus Public Equities Advisors, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,707,287.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,707,287.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,707,287.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Invus Public Equities, L.P. holds an aggregate of 2,902,429 American Depositary Shares ("ADSs"), each of which ADS represents three ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer").

SCHEDULE 13G

CUSIP Number(s): 82686Q101

1

Names of Reporting Persons

Invus Global Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,707,287.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,707,287.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,707,287.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Invus Public Equities, L.P. holds an aggregate of 2,902,429 American Depositary Shares ("ADSs"), each of which ADS represents three ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer").

SCHEDULE 13G

CUSIP Number(s): 82686Q101

1

Names of Reporting Persons

Siren, L.L.C.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,707,287.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,707,287.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,707,287.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Invus Public Equities, L.P. holds an aggregate of 2,902,429 American Depositary Shares ("ADSs"), each of which ADS represents three ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer").

SCHEDULE 13G

CUSIP Number(s): 82686Q101

1

Names of Reporting Persons

Avicenna Life Sci Master Fund LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,227,027.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,227,027.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,227,027.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.9 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Avicenna Life Sci Master Fund LP holds an aggregate of 409,009 American Depositary Shares ("ADSs"), each of which ADS represents three ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer").

SCHEDULE 13G

CUSIP Number(s): 82686Q101

1

Names of Reporting Persons

Avicenna Life Sci Master GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,227,027.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,227,027.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,227,027.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.9 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Avicenna Life Sci Master Fund LP holds an aggregate of 409,009 American Depositary Shares ("ADSs"), each of which ADS represents three ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer").

SCHEDULE 13G

CUSIP Number(s): 82686Q101

1

Names of Reporting Persons

Ulys, L.L.C.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,227,027.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,227,027.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,227,027.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.9 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Avicenna Life Sci Master Fund LP holds an aggregate of 409,009 American Depositary Shares ("ADSs"), each of which ADS represents three ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer").

SCHEDULE 13G

CUSIP Number(s): 82686Q101

1

Names of Reporting Persons

Raymond Debbane

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PANAMA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 9,934,314.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 9,934,314.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,934,314.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.0 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Invus Public Equities, L.P. holds an aggregate of 2,902,429 American Depositary Shares ("ADSs"), and Avicenna Life Sci Master Fund LP holds an aggregate of 409,009 ADSs, each of which ADS represents three ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer").

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Silence Therapeutics plc
(b)	Address of issuer's principal executive offices: 72 Hammersmith Grove, Office 205, London, United Kingdom, W6 7AP
Item 2.
(a)	Name of person filing: See Item 2(c) below.
(b)	Address or principal business office or, if none, residence: See Item 2(c) below.
(c)	Citizenship: (i) Invus Public Equities, L.P. ("Invus Public Equities") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Bermuda limited partnership (ii) Invus Public Equities Advisors, LLC ("Invus PE Advisors") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (iii) Invus Global Management, LLC ("Global Management") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (iv) Siren, L.L.C. ("Siren") c/o The Invus Group, LLC, 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (v) Avicenna Life Sci Master Fund LP ("Avicenna Fund") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Cayman Islands limited partnership (vi) Avicenna Life Sci Master GP LLC ("Avicenna GP") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (vii) Ulys, L.L.C. ("Ulys") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (viii) Mr. Raymond Debbane 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Panama The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
(d)	Title of class of securities: Ordinary share, nominal value 0.05 GBP per share
(e)	CUSIP No.: 82686Q101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of June 30, 2026, Invus Public Equities beneficially held 8,707,287 ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer"), represented by an aggregate of 2,902,429 American Depositary Shares ("ADSs") directly held by Invus Public Equities, and Avicenna Fund beneficially held 1,227,027 Shares represented by an aggregate of 409,009 ADSs directly held by Avicenna Fund, each of which ADS represents three Shares. Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares beneficially held by Invus Public Equities. Global Management, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Siren, as the managing member of Global Management, controls Global Management and, accordingly, may be deemed to beneficially own the Shares that Global Management may be deemed to beneficially own. Avicenna GP, as the general partner of Avicenna Fund, controls Avicenna Fund and, accordingly, may be deemed to beneficially own the Shares beneficially held by Avicenna Fund. Ulys, as the managing member of Avicenna GP, controls Avicenna GP and, accordingly, may be deemed to beneficially own the Shares that Avicenna GP may be deemed to beneficially own. Mr. Raymond Debbane, as the managing member of Siren and Ulys, controls Siren and Ulys and, accordingly, may be deemed to beneficially own the Shares that Siren and Ulys may be deemed to beneficially own.
(b)	Percent of class: As of June 30, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person's cover page. Calculations of the percentage of Shares beneficially owned are based on 141,703,840 Shares outstanding as of April 30, 2026 based on information set forth in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See each cover page hereof.
	(ii) Shared power to vote or to direct the vote: See each cover page hereof.
	(iii) Sole power to dispose or to direct the disposition of: See each cover page hereof.
	(iv) Shared power to dispose or to direct the disposition of: See each cover page hereof.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

Each of the Reporting Persons hereby makes the following certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Invus Public Equities, L.P.

Signature:	/s/ Raymond Debbane
Name/Title:	Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner
Date:	08/13/2026

Invus Public Equities Advisors, LLC

Signature:	/s/ Raymond Debbane
Name/Title:	Raymond Debbane, President
Date:	08/13/2026

Invus Global Management, LLC

Signature:	/s/ Raymond Debbane
Name/Title:	Raymond Debbane, President
Date:	08/13/2026

Siren, L.L.C.

Signature:	/s/ Raymond Debbane
Name/Title:	Raymond Debbane, President
Date:	08/13/2026

Avicenna Life Sci Master Fund LP

Signature:	/s/ Raymond Debbane
Name/Title:	Raymond Debbane, Chief Executive Officer of Avicenna Life Sci Master GP LLC, its general partner
Date:	08/13/2026

Avicenna Life Sci Master GP LLC

Signature:	/s/ Raymond Debbane
Name/Title:	Raymond Debbane, Chief Executive Officer
Date:	08/13/2026

Ulys, L.L.C.

Signature:	/s/ Raymond Debbane
Name/Title:	Raymond Debbane, President
Date:	08/13/2026

Raymond Debbane

Signature:	/s/ Raymond Debbane
Name/Title:	Raymond Debbane
Date:	08/13/2026